Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

MRI Signal Intensity and Parkinsonism in Manganese-Exposed Workers.

Criswell SR, Nielsen SS, Warden MN, Flores HP, Lenox-Krug J, Racette S, Sheppard L, Checkoway H, Racette BA.

J Occup Environ Med. 2019 Aug;61(8):641-645. doi: 10.1097/JOM.0000000000001634.

PMID:
31348423
2.

Transplant and risk of Parkinson disease.

Fan J, Searles Nielsen S, Faust IM, Racette BA.

Parkinsonism Relat Disord. 2019 Jun;63:149-155. doi: 10.1016/j.parkreldis.2019.02.013. Epub 2019 Feb 14.

PMID:
30827837
3.

The reproducibility of urinary ions in manganese exposed workers.

Baker MG, Lin YS, Simpson CD, Shireman LM, Searles Nielsen S, Racette BA, Seixas N.

J Trace Elem Med Biol. 2019 Jan;51:204-211. doi: 10.1016/j.jtemb.2018.11.001. Epub 2018 Nov 3.

PMID:
30466932
4.

β2-adrenoreceptor medications and risk of Parkinson disease.

Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA.

Ann Neurol. 2018 Nov;84(5):683-693. doi: 10.1002/ana.25341. Epub 2018 Oct 30.

PMID:
30225948
5.

Selective D2 receptor PET in manganese-exposed workers.

Criswell SR, Warden MN, Searles Nielsen S, Perlmutter JS, Moerlein SM, Sheppard L, Lenox-Krug J, Checkoway H, Racette BA.

Neurology. 2018 Sep 11;91(11):e1022-e1030. doi: 10.1212/WNL.0000000000006163. Epub 2018 Aug 10.

6.

Immunosuppressants and risk of Parkinson disease.

Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles Nielsen S.

Ann Clin Transl Neurol. 2018 May 31;5(7):870-875. doi: 10.1002/acn3.580. eCollection 2018 Jul.

7.

Author response: A predictive model to identify Parkinson disease from administrative claims data.

Searles Nielsen S, Racette BA.

Neurology. 2018 Jul 10;91(2):104. doi: 10.1212/WNL.0000000000005767. No abstract available.

PMID:
29987183
8.

Inflammatory bowel disease and risk of Parkinson's disease in medicare beneficiaries.

Camacho-Soto A, Searles Nielsen S, Racette BA.

Parkinsonism Relat Disord. 2018 Dec;57:77. doi: 10.1016/j.parkreldis.2018.06.028. Epub 2018 Jun 27. No abstract available.

PMID:
29983328
9.

Use of medical care biases associations between Parkinson disease and other medical conditions.

Gross A, Racette BA, Camacho-Soto A, Dube U, Searles Nielsen S.

Neurology. 2018 Jun 12;90(24):e2155-e2165. doi: 10.1212/WNL.0000000000005678. Epub 2018 May 9.

10.

Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries.

Camacho-Soto A, Gross A, Searles Nielsen S, Dey N, Racette BA.

Parkinsonism Relat Disord. 2018 May;50:23-28. doi: 10.1016/j.parkreldis.2018.02.008. Epub 2018 Feb 9.

11.

Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data.

Camacho-Soto A, Warden MN, Searles Nielsen S, Salter A, Brody DL, Prather H, Racette BA.

Ann Neurol. 2017 Nov;82(5):744-754. doi: 10.1002/ana.25074. Epub 2017 Oct 31.

12.

A predictive model to identify Parkinson disease from administrative claims data.

Searles Nielsen S, Warden MN, Camacho-Soto A, Willis AW, Wright BA, Racette BA.

Neurology. 2017 Oct 3;89(14):1448-1456. doi: 10.1212/WNL.0000000000004536. Epub 2017 Sep 1.

13.

[18F]FDOPA positron emission tomography in manganese-exposed workers.

Criswell SR, Nielsen SS, Warden M, Perlmutter JS, Moerlein SM, Flores HP, Huang J, Sheppard L, Seixas N, Checkoway H, Racette BA.

Neurotoxicology. 2018 Jan;64:43-49. doi: 10.1016/j.neuro.2017.07.004. Epub 2017 Jul 8.

14.

Parkinsonism Signs and Symptoms in Agricultural Pesticide Handlers in Washington State.

Searles Nielsen S, Hu SC, Checkoway H, Negrete M, Palmández P, Bordianu T, Racette BA, Simpson CD.

J Agromedicine. 2017;22(3):215-221. doi: 10.1080/1059924X.2017.1317684.

15.

A screening tool to detect clinical manganese neurotoxicity.

Racette BA, Gross A, Criswell SR, Checkoway H, Searles Nielsen S.

Neurotoxicology. 2018 Jan;64:12-18. doi: 10.1016/j.neuro.2017.02.009. Epub 2017 Mar 6.

16.

Pathologic correlates of supranuclear gaze palsy with parkinsonism.

Martin WRW, Hartlein J, Racette BA, Cairns N, Perlmutter JS.

Parkinsonism Relat Disord. 2017 May;38:68-71. doi: 10.1016/j.parkreldis.2017.02.027. Epub 2017 Feb 24.

17.

Dose-dependent progression of parkinsonism in manganese-exposed welders.

Racette BA, Searles Nielsen S, Criswell SR, Sheppard L, Seixas N, Warden MN, Checkoway H.

Neurology. 2017 Jan 24;88(4):344-351. doi: 10.1212/WNL.0000000000003533. Epub 2016 Dec 28.

18.

Cognitive control dysfunction in workers exposed to manganese-containing welding fume.

Al-Lozi A, Nielsen SS, Hershey T, Birke A, Checkoway H, Criswell SR, Racette BA.

Am J Ind Med. 2017 Feb;60(2):181-188. doi: 10.1002/ajim.22675. Epub 2016 Nov 15.

19.

Parkinson disease and cognitive impairment: Five new things.

Davis AA, Racette B.

Neurol Clin Pract. 2016 Oct;6(5):452-458. Review.

20.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

21.

Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression.

Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C.

Neurobiol Aging. 2016 Jan;37:209.e1-209.e7. doi: 10.1016/j.neurobiolaging.2015.09.014. Epub 2015 Sep 30.

22.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
23.

Nursing home and end-of-life care in Parkinson disease.

Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, Willis AW.

Neurology. 2015 Aug 4;85(5):413-9. doi: 10.1212/WNL.0000000000001715. Epub 2015 Jul 2.

24.

Physician response to a medication alert system in inpatients with levodopa-treated diseases.

Morris M, Willis AW, Searles Nielsen S, McCann F, Birke A, Racette BA.

Neurology. 2015 Aug 4;85(5):420-4. doi: 10.1212/WNL.0000000000001745. Epub 2015 Jun 19.

25.

Time to change the blind men and the elephant approach to Parkinson disease?

Racette BA, Willis AW.

Neurology. 2015 Jul 14;85(2):190-6. doi: 10.1212/WNL.0000000000001739. Epub 2015 Jun 12. Review.

26.

Natural history of multiple system atrophy in the USA: a prospective cohort study.

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J.

Lancet Neurol. 2015 Jul;14(7):710-9. doi: 10.1016/S1474-4422(15)00058-7. Epub 2015 May 27.

27.

Ex vivo magnetic resonance imaging in South African manganese mine workers.

Criswell SR, Nelson G, Gonzalez-Cuyar LF, Huang J, Shimony JS, Checkoway H, Simpson CD, Dills R, Seixas NS, Racette BA.

Neurotoxicology. 2015 Jul;49:8-14. doi: 10.1016/j.neuro.2015.04.002. Epub 2015 Apr 23.

28.

Inducible nitric oxide synthase gene methylation and parkinsonism in manganese-exposed welders.

Searles Nielsen S, Checkoway H, Criswell SR, Farin FM, Stapleton PL, Sheppard L, Racette BA.

Parkinsonism Relat Disord. 2015 Apr;21(4):355-60. doi: 10.1016/j.parkreldis.2015.01.007. Epub 2015 Jan 17.

29.

Neurological outcomes associated with low-level manganese exposure in an inception cohort of asymptomatic welding trainees.

Baker MG, Criswell SR, Racette BA, Simpson CD, Sheppard L, Checkoway H, Seixas NS.

Scand J Work Environ Health. 2015 Jan;41(1):94-101. doi: 10.5271/sjweh.3466. Epub 2014 Nov 7.

30.

Formulations of hormone therapy and risk of Parkinson's disease.

Lundin JI, Ton TG, LaCroix AZ, Longstreth WT, Franklin GM, Swanson PD, Smith-Weller T, Racette BA, Checkoway H.

Mov Disord. 2014 Nov;29(13):1631-6. doi: 10.1002/mds.26037. Epub 2014 Sep 25.

31.

A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia.

Vemula SR, Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Hedera P, Truong DD, Blitzer A, Rudzińska M, Momčilović D, Jinnah HA, Frei K, Pfeiffer RF, LeDoux MS.

Mol Genet Genomic Med. 2014 May;2(3):261-72. doi: 10.1002/mgg3.67. Epub 2014 Feb 11.

32.

Supply and demand analysis of the current and future US neurology workforce.

Racette BA, Holtzman DM, Dall TM, Drogan O.

Neurology. 2014 Jun 17;82(24):2254-5. doi: 10.1212/WNL.0000000000000509. No abstract available.

PMID:
24935638
33.

Blood manganese as an exposure biomarker: state of the evidence.

Baker MG, Simpson CD, Stover B, Sheppard L, Checkoway H, Racette BA, Seixas NS.

J Occup Environ Hyg. 2014;11(4):210-7. doi: 10.1080/15459624.2013.852280. Review.

34.

Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures.

Harris-Hayes M, Willis AW, Klein SE, Czuppon S, Crowner B, Racette BA.

J Bone Joint Surg Am. 2014 Feb 19;96(4):e27. doi: 10.2106/JBJS.L.01317.

35.

Quantitative neuropathology associated with chronic manganese exposure in South African mine workers.

Gonzalez-Cuyar LF, Nelson G, Criswell SR, Ho P, Lonzanida JA, Checkoway H, Seixas N, Gelman BB, Evanoff BA, Murray J, Zhang J, Racette BA.

Neurotoxicology. 2014 Dec;45:260-6. doi: 10.1016/j.neuro.2013.12.008. Epub 2013 Dec 26.

36.

Disparities in deep brain stimulation surgery among insured elders with Parkinson disease.

Willis AW, Schootman M, Kung N, Wang XY, Perlmutter JS, Racette BA.

Neurology. 2014 Jan 14;82(2):163-71. doi: 10.1212/WNL.0000000000000017. Epub 2013 Dec 11.

37.

Manganism in the 21st century: the Hanninen lecture.

Racette BA.

Neurotoxicology. 2014 Dec;45:201-7. doi: 10.1016/j.neuro.2013.09.007. Epub 2013 Oct 19. Review.

38.

Variables associated with return to sport following anterior cruciate ligament reconstruction: a systematic review.

Czuppon S, Racette BA, Klein SE, Harris-Hayes M.

Br J Sports Med. 2014 Mar;48(5):356-64. doi: 10.1136/bjsports-2012-091786. Epub 2013 Oct 11. Review.

39.

Screening for early detection of parkinsonism using a self-administered questionnaire: a cross-sectional epidemiologic study.

Lundin JI, Checkoway H, Criswell SR, Hobson AJ, Harris RC, Swisher LM, Evanoff BA, Racette BA.

Neurotoxicology. 2014 Dec;45:232-7. doi: 10.1016/j.neuro.2013.08.010. Epub 2013 Sep 12.

40.

Bright light exposure reduces TH-positive dopamine neurons: implications of light pollution in Parkinson's disease epidemiology.

Romeo S, Viaggi C, Di Camillo D, Willis AW, Lozzi L, Rocchi C, Capannolo M, Aloisi G, Vaglini F, Maccarone R, Caleo M, Missale C, Racette BA, Corsini GU, Maggio R.

Sci Rep. 2013;3:1395. doi: 10.1038/srep01395.

41.

A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ.

F1000Res. 2013 Jul 9;2:150. doi: 10.12688/f1000research.2-150.v1. eCollection 2013.

42.

DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease.

Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J.

Sci Rep. 2012;2:954. doi: 10.1038/srep00954. Epub 2012 Dec 11.

43.

Parkinson disease is not associated with C9ORF72 repeat expansions.

Harms MB, Neumann D, Benitez BA, Cooper B, Carrell D, Racette BA, Perlmutter JS, Goate A, Cruchaga C.

Neurobiol Aging. 2013 May;34(5):1519.e1-2. doi: 10.1016/j.neurobiolaging.2012.10.001. Epub 2012 Oct 30.

44.

Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States.

Willis AW, Schootman M, Kung N, Racette BA.

Parkinsonism Relat Disord. 2013 Feb;19(2):202-6. doi: 10.1016/j.parkreldis.2012.09.014. Epub 2012 Oct 17.

45.

Neurologist-associated reduction in PD-related hospitalizations and health care expenditures.

Willis AW, Schootman M, Tran R, Kung N, Evanoff BA, Perlmutter JS, Racette BA.

Neurology. 2012 Oct 23;79(17):1774-80. doi: 10.1212/WNL.0b013e3182703f92. Epub 2012 Oct 10.

46.

Clinical presentation and self-reported patterns of pain and function in patients with plantar heel pain.

Klein SE, Dale AM, Hayes MH, Johnson JE, McCormick JJ, Racette BA.

Foot Ankle Int. 2012 Sep;33(9):693-8.

47.

Increased risk of parkinsonism associated with welding exposure.

Racette BA, Criswell SR, Lundin JI, Hobson A, Seixas N, Kotzbauer PT, Evanoff BA, Perlmutter JS, Zhang J, Sheppard L, Checkoway H.

Neurotoxicology. 2012 Oct;33(5):1356-61. doi: 10.1016/j.neuro.2012.08.011. Epub 2012 Sep 3.

48.

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS.

Arch Neurol. 2012 Oct;69(10):1326-31.

49.

Botulinum toxin effects on gasatrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulceration.

Hastings MK, Mueller MJ, Sinacore DR, Strube MJ, Crowner BE, Johnson JE, Racette BR.

Foot Ankle Int. 2012 May;33(5):363-70. doi: 10.3113/FAI.2012.0363.

50.

Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders.

Criswell SR, Perlmutter JS, Huang JL, Golchin N, Flores HP, Hobson A, Aschner M, Erikson KM, Checkoway H, Racette BA.

Occup Environ Med. 2012 Jun;69(6):437-43. doi: 10.1136/oemed-2011-100119. Epub 2012 Mar 23.

Supplemental Content

Loading ...
Support Center